Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx
The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines.
Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 10 of 12
Imugene reveals new data on cancer vaccine programs
Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone.
Imugene gets development roadmap for cancer vaccine from FDA meeting
The company had a pre-investigational new drug (IND) meeting with the FDA last month.
Imugene doses milestone first patient for cancer vaccine trial
The first patient was dosed in the Eastern European country of Moldova.
Imugene to make further cancer vaccine research presentations at AACR annual meeting
The AACR annual meeting will be held in Atlanta Georgia, between March 29 and April 3.
Imugene to present cancer vaccine research at AACR annual meeting
The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
Imugene has cancer vaccine trial data published in prestigious medical journal
Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.
Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Imugene begins manufacture of its innovative cancer vaccine for trials
KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody.
Imugene signs exclusive, world-wide licence for cancer vaccine
Imugene is a clinical stage immuno-oncology company.
Imugene pounces on material acquisition
Imugene is an immuno-oncology company focused on gastric cancer.
Imugene’s shares surge higher following early promise in gastric cancer trial
The company is well funded with a cash balance of circa $12 million as at 31 December 2017.
Imugene targets cash injection for immuno-oncology clinical testing
The halt will remain in place until Thursday 23rd November 2017.
Imugene granted Canadian patent for proprietary cancer vaccine
Immunotherapies are predicted to generate sales of US$36 billion by 2025.
Imugene raises $3M from option plan to advance immunotherapy studies
Imugene is developing an immunotherapy to treat gastric cancer.
Imugene Ltd appoints Leslie Chong to chief executive officer
Imugene Ltd (ASX:IMU) has promoted Leslie Chong to the position of chief executive officer, as the company prepares for the critical milestone of dosing the patients in the gastric cancer Phase 1b/2 clinical trial in Asia.
Imugene gets ready to raise
Imugene Ltd (ASX:IMU) has been granted a trading halt by the ASX, pending details of a capital raising.